Cantor Fitzgerald Reaffirms Overweight Rating for Ascendis Pharma A/S (NASDAQ:ASND)

Cantor Fitzgerald reaffirmed their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report released on Friday,Benzinga reports. Cantor Fitzgerald currently has a $170.00 price objective on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the company. StockNews.com downgraded Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Citigroup increased their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Oppenheimer reissued an “outperform” rating and issued a $190.00 price target (up previously from $180.00) on shares of Ascendis Pharma A/S in a research report on Tuesday, September 17th. The Goldman Sachs Group upped their price target on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Finally, TD Cowen lifted their price objective on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and an average price target of $191.77.

Ascendis Pharma A/S Stock Up 1.8 %

ASND opened at $126.51 on Friday. Ascendis Pharma A/S has a twelve month low of $90.13 and a twelve month high of $161.00. The company’s 50-day moving average price is $132.30 and its two-hundred day moving average price is $132.60. The stock has a market cap of $7.67 billion, a price-to-earnings ratio of -15.66 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. As a group, sell-side analysts anticipate that Ascendis Pharma A/S will post -7.3 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently made changes to their positions in ASND. Frazier Life Sciences Management L.P. purchased a new position in Ascendis Pharma A/S during the third quarter worth about $19,908,000. Public Employees Retirement System of Ohio bought a new stake in shares of Ascendis Pharma A/S during the 3rd quarter valued at about $1,101,000. Groupama Asset Managment bought a new stake in shares of Ascendis Pharma A/S during the 3rd quarter valued at about $60,000. Nomura Asset Management Co. Ltd. grew its holdings in shares of Ascendis Pharma A/S by 42.5% during the third quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company’s stock worth $2,688,000 after purchasing an additional 5,371 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Ascendis Pharma A/S in the third quarter worth approximately $886,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.